Paclitaxel in self-micro emulsifying formulations: Oral bioavailability study in mice

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 768-776

  Oostendorp, Roos L ^a   Buckle, T ^a   Lambert, G ^b   Garrigue, J S ^b   Beijnen, J H ^a,c   Schellens, J H M ^a,c   Van Tellingen, O ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Novagali Pharma   (France)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cyclosporin A; Oral bioavailability; Oral paclitaxel; SMEOF formulation

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; PACLITAXEL; POLYSORBATE 80; EMULSION; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG UPTAKE; FEMALE; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SELF MICRO EMULSIFYING OILY FORMULATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; DEFICIENCY; EMULSION; FECES; KNOCKOUT MOUSE; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; TIME FACTOR;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; FECES; FEMALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PACLITAXEL; TIME FACTORS;

EID: 84861206177     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9421-7     Document Type: Article

References (26)

1. Huizing MT, Misser VH, Pieters RC, Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Invest 13:381-404
2. Rowinsky EK, Wright M, Monsarrat B, Donehower RC (1994) Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann Oncol 5(Suppl 6):S7-S16, S7-16
3. Dorr RT (1994) Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28:S-S14
4. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115
5. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330-335
6. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457
7. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115
8. Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103-110
9. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035
10. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566-575
11. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183
12. van Asperen J, van Tellingen O, Van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293-2297
13. Meerum Terwogt JM, Beijnen JH, Bokkel Huinink WW, Rosing H, Schellens JH (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352:285
14. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathot RA, Marcus S, van Tinteren H, Baas P (2002) Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-smallcell lung cancer. J Clin Oncol 20:4508-4516
15. Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathot RA, Rosing H, Schot ME, van Tinteren H, Schellens JH (2003) Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol 14:197-204
16. Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH (2006) Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer 95:794-800
17. Malingre MM, Schellens JH, van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Bokkel Huinink WW, Beijnen JH (2001) The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 85:1472-1477
18. Bardelmeijer HA, Ouwehand M, Malingre MM, Schellens JH, Beijnen JH, van Tellingen O (2002) Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 49:119-125
19. Malingre MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH (2000) Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18:2468-2475
20. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S (2003) Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J Pharm Sci 92:2411-2418
21. Gershanik T, Benita S (2000) Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50:179-188
22. Chang T, Benet LZ, Hebert MF (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303
23. Boudreaux JP, Hayes DH, Mizrahi S, Maggiore P, Blazek J, Dick D (1993) Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. Transplant Proc 25:1875
24. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1995) Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase highperformance liquid chromatography. J Chromatogr B Biomed Appl 664:383-391
25. Huizing MT, Sparreboom A, Rosing H, van Tellingen O, Pinedo HM, Beijnen JH (1995) Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 674:261-268
26. Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH (2006) A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729-734